JP2018521993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521993A5 JP2018521993A5 JP2017566000A JP2017566000A JP2018521993A5 JP 2018521993 A5 JP2018521993 A5 JP 2018521993A5 JP 2017566000 A JP2017566000 A JP 2017566000A JP 2017566000 A JP2017566000 A JP 2017566000A JP 2018521993 A5 JP2018521993 A5 JP 2018521993A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- day
- effective amount
- therapeutically effective
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562180914P | 2015-06-17 | 2015-06-17 | |
| US62/180,914 | 2015-06-17 | ||
| PCT/US2016/038110 WO2016205671A1 (en) | 2015-06-17 | 2016-06-17 | Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182191A Division JP6675037B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
| JP2019182192A Division JP7036782B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521993A JP2018521993A (ja) | 2018-08-09 |
| JP2018521993A5 true JP2018521993A5 (https=) | 2019-07-04 |
| JP6599484B2 JP6599484B2 (ja) | 2019-10-30 |
Family
ID=57546446
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017566000A Active JP6599484B2 (ja) | 2015-06-17 | 2016-06-17 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
| JP2019182192A Active JP7036782B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
| JP2019182191A Active JP6675037B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019182192A Active JP7036782B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
| JP2019182191A Active JP6675037B2 (ja) | 2015-06-17 | 2019-10-02 | ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US10471087B2 (https=) |
| EP (3) | EP3505174B1 (https=) |
| JP (3) | JP6599484B2 (https=) |
| KR (3) | KR20250048602A (https=) |
| CN (2) | CN107847512A (https=) |
| AU (3) | AU2016280293B2 (https=) |
| BR (2) | BR112017027079B1 (https=) |
| CA (1) | CA2989653A1 (https=) |
| CY (2) | CY1122605T1 (https=) |
| DK (2) | DK3310362T3 (https=) |
| ES (2) | ES2748556T3 (https=) |
| HK (1) | HK1252133A1 (https=) |
| HR (2) | HRP20191794T1 (https=) |
| HU (2) | HUE046399T2 (https=) |
| IL (3) | IL275256B2 (https=) |
| LT (2) | LT3505174T (https=) |
| MX (2) | MX2017016425A (https=) |
| PL (2) | PL3505174T3 (https=) |
| PT (2) | PT3505174T (https=) |
| RS (2) | RS60572B1 (https=) |
| RU (1) | RU2721492C2 (https=) |
| SI (2) | SI3310362T1 (https=) |
| SM (2) | SMT202000399T1 (https=) |
| WO (1) | WO2016205671A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| US10292996B2 (en) * | 2015-03-26 | 2019-05-21 | The Trustees Of Columbia University In The City Of New York | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome |
| LT3505174T (lt) * | 2015-06-17 | 2020-09-10 | The Trustees Of Columbia University In The City Of New York | Deoksinukleozidų terapija, skirta gydyti ligas, kurias sukelia nesubalansuoti nukleotidų kiekiai, įskaitant mitochondrinės dnr išsekimo sindromus |
| WO2017112701A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| ES3024232T3 (en) | 2015-12-22 | 2025-06-04 | Zogenix International Ltd | Fenfluramine compositions and methods of preparing the same |
| SG11201900975XA (en) | 2016-08-24 | 2019-03-28 | Zogenix International Ltd | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
| US11649442B2 (en) | 2017-09-08 | 2023-05-16 | The Regents Of The University Of California | RNA-guided endonuclease fusion polypeptides and methods of use thereof |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| CA3096264A1 (en) * | 2018-04-12 | 2019-10-17 | Modis Therapeutics Inc. | Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools |
| CN112312929A (zh) | 2018-04-18 | 2021-02-02 | 纽约市哥伦比亚大学理事会 | 用于包括线粒体dna耗竭综合征在内的由不平衡的核苷酸库引起的疾病的基因疗法 |
| WO2019216919A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| EA202191079A1 (ru) | 2018-11-19 | 2021-09-20 | Зодженикс Интернэшнл Лимитед | Способы лечения синдрома ретта с применением фенфлурамина |
| CN114929240B (zh) * | 2019-08-19 | 2024-10-29 | 周格尼克斯公司 | 脱氧胞苷的多晶型形式、包含其的组合物和用途 |
| IL322998A (en) * | 2019-09-05 | 2025-10-01 | Mitorainbow Therapeutics Inc | Treatment of mitochondrial DNA depletion disorders |
| JP2023518395A (ja) | 2020-03-19 | 2023-05-01 | インテリア セラピューティクス，インコーポレイテッド | 指向性ゲノム編集のための方法及び組成物 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| US20220096514A1 (en) * | 2020-09-29 | 2022-03-31 | Zogenix International Limited | Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine |
| US20240041910A1 (en) * | 2020-12-28 | 2024-02-08 | Yamasa Corporation | Muscular atrophy inhibitor and method for inhibiting muscular atrophy |
| WO2022204555A1 (en) * | 2021-03-26 | 2022-09-29 | Zogenix Mds, Inc. | Aqueous solutions containing purines and pyrimidines and uses thereof |
| US20230000890A1 (en) * | 2021-06-18 | 2023-01-05 | Zogenix Mds, Inc. | Prodrugs of Deoxynucleosides for Treatment of Mitochondrial Diseases Caused by Unbalanced Nucleotide Pools |
| CA3261416A1 (en) * | 2022-07-12 | 2024-01-18 | Ucb Biosciences, Inc. | METHODS TO INCREASE THE BIOAVAILABILITY OF NUCLEOSID MEDICINAL AGENTS |
| EP4687918A2 (en) * | 2023-03-30 | 2026-02-11 | The Trustees Of Columbia University In The City Of New York | Pharmacological therapy for mitochondrial dna depletion deletions syndrome involving mutations in the guk1 gene |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101120947B (zh) * | 1998-08-10 | 2010-11-24 | 艾丹尼克斯(开曼)有限公司 | 用于治疗乙型肝炎的β-L-2′-脱氧-核苷 |
| EP1808177B1 (en) * | 1999-02-23 | 2018-08-08 | The Regents of The University of California | Methods of treatment of mitochondrial disorders |
| EA005890B1 (ru) * | 2000-05-26 | 2005-06-30 | Айденикс (Кайман) Лимитед | СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ |
| WO2012125848A2 (en) | 2011-03-16 | 2012-09-20 | Baylor College Of Medicine | A method for comprehensive sequence analysis using deep sequencing technology |
| US10292996B2 (en) | 2015-03-26 | 2019-05-21 | The Trustees Of Columbia University In The City Of New York | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome |
| US11337980B2 (en) * | 2015-06-05 | 2022-05-24 | Fundació Hospital Universitari Vall D'hebron-Institut De Recerca | Treatment of mitochondrial diseases |
| LT3505174T (lt) * | 2015-06-17 | 2020-09-10 | The Trustees Of Columbia University In The City Of New York | Deoksinukleozidų terapija, skirta gydyti ligas, kurias sukelia nesubalansuoti nukleotidų kiekiai, įskaitant mitochondrinės dnr išsekimo sindromus |
-
2016
- 2016-06-17 LT LTEP19156021.8T patent/LT3505174T/lt unknown
- 2016-06-17 ES ES16812537T patent/ES2748556T3/es active Active
- 2016-06-17 SM SM20200399T patent/SMT202000399T1/it unknown
- 2016-06-17 SI SI201630439T patent/SI3310362T1/sl unknown
- 2016-06-17 KR KR1020257009842A patent/KR20250048602A/ko active Pending
- 2016-06-17 MX MX2017016425A patent/MX2017016425A/es active IP Right Grant
- 2016-06-17 SM SM20190571T patent/SMT201900571T1/it unknown
- 2016-06-17 JP JP2017566000A patent/JP6599484B2/ja active Active
- 2016-06-17 DK DK16812537.5T patent/DK3310362T3/da active
- 2016-06-17 US US15/736,092 patent/US10471087B2/en active Active
- 2016-06-17 DK DK19156021.8T patent/DK3505174T3/da active
- 2016-06-17 KR KR1020227002790A patent/KR20220018623A/ko not_active Ceased
- 2016-06-17 RU RU2018101305A patent/RU2721492C2/ru active
- 2016-06-17 CA CA2989653A patent/CA2989653A1/en active Pending
- 2016-06-17 KR KR1020187001496A patent/KR20180039624A/ko not_active Ceased
- 2016-06-17 EP EP19156021.8A patent/EP3505174B1/en active Active
- 2016-06-17 PT PT191560218T patent/PT3505174T/pt unknown
- 2016-06-17 PT PT168125375T patent/PT3310362T/pt unknown
- 2016-06-17 IL IL275256A patent/IL275256B2/en unknown
- 2016-06-17 HU HUE16812537A patent/HUE046399T2/hu unknown
- 2016-06-17 EP EP19178700.1A patent/EP3569236A1/en active Pending
- 2016-06-17 MX MX2020000269A patent/MX389016B/es unknown
- 2016-06-17 HK HK18111524.2A patent/HK1252133A1/zh unknown
- 2016-06-17 CN CN201680045355.XA patent/CN107847512A/zh active Pending
- 2016-06-17 PL PL19156021T patent/PL3505174T3/pl unknown
- 2016-06-17 CN CN202310757609.2A patent/CN116726035A/zh active Pending
- 2016-06-17 BR BR112017027079-0A patent/BR112017027079B1/pt active IP Right Grant
- 2016-06-17 ES ES19156021T patent/ES2808148T3/es active Active
- 2016-06-17 AU AU2016280293A patent/AU2016280293B2/en active Active
- 2016-06-17 EP EP16812537.5A patent/EP3310362B1/en active Active
- 2016-06-17 RS RS20200779A patent/RS60572B1/sr unknown
- 2016-06-17 LT LT16812537T patent/LT3310362T/lt unknown
- 2016-06-17 BR BR122020021913-0A patent/BR122020021913B1/pt active IP Right Grant
- 2016-06-17 HU HUE19156021A patent/HUE050678T2/hu unknown
- 2016-06-17 HR HRP20191794TT patent/HRP20191794T1/hr unknown
- 2016-06-17 SI SI201630830T patent/SI3505174T1/sl unknown
- 2016-06-17 PL PL16812537T patent/PL3310362T3/pl unknown
- 2016-06-17 RS RS20191295A patent/RS59724B1/sr unknown
- 2016-06-17 WO PCT/US2016/038110 patent/WO2016205671A1/en not_active Ceased
-
2017
- 2017-12-14 IL IL256331A patent/IL256331B/en active IP Right Grant
-
2019
- 2019-09-26 US US16/583,852 patent/US11110111B2/en active Active
- 2019-10-02 JP JP2019182192A patent/JP7036782B2/ja active Active
- 2019-10-02 JP JP2019182191A patent/JP6675037B2/ja active Active
- 2019-10-30 CY CY20191101127T patent/CY1122605T1/el unknown
-
2020
- 2020-06-09 IL IL275255A patent/IL275255B/en active IP Right Grant
- 2020-06-15 HR HRP20200949TT patent/HRP20200949T1/hr unknown
- 2020-06-17 AU AU2020204042A patent/AU2020204042B2/en active Active
- 2020-06-25 CY CY20201100578T patent/CY1123107T1/el unknown
-
2021
- 2021-04-28 US US17/242,822 patent/US11666592B2/en active Active
- 2021-10-11 AU AU2021250841A patent/AU2021250841B2/en active Active
-
2023
- 2023-04-24 US US18/138,432 patent/US12251392B2/en active Active
-
2025
- 2025-02-11 US US19/050,489 patent/US20250360154A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521993A5 (https=) | ||
| HRP20200949T1 (hr) | Deoksinukleozidna terapija bolesti uzrokovanih neurevnoteženim fondovima nukleotida, uključujući sindrome manjka mitohondrijske dna | |
| JP2016533379A5 (https=) | ||
| JP2017036288A5 (https=) | ||
| ES2797900T3 (es) | Compuestos y combinaciones para el tratamiento del VIH | |
| RU2017142555A (ru) | Способ стимуляции кишечной флоры | |
| JP2014077003A5 (https=) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2015078220A5 (https=) | ||
| JP2012523435A (ja) | Ｄｎａ損傷因子増強のためのチェックポイントキナーゼ１阻害剤 | |
| RU2018139655A (ru) | Бифидобактерии для увеличения безжировой массы тела | |
| JP2019505529A5 (https=) | ||
| Sey et al. | The gut-lung axis: the impact of the gut mycobiome on pulmonary diseases and infections | |
| JP2016539156A5 (https=) | ||
| FI3710000T3 (fi) | Tradipitantti käytettäväksi gastropareesin hoidossa | |
| JP2019038796A5 (https=) | ||
| NO20073813L (no) | Kladribinregime for behandling av multippel sklerose | |
| JP2021073257A5 (https=) | ||
| JP2019038797A5 (https=) | ||
| JP2009517391A5 (ja) | 胃腸障害の処置のための医薬組成物 | |
| JP2019504860A5 (https=) | ||
| CN1615136A (zh) | 包含埃坡霉素和抗代谢物的组合 | |
| JP2016014051A5 (https=) | ||
| Maciaszek | Muscles training for the stability of the spine | |
| CA3037779A1 (en) | Treatment of inflammatory bowel disease with nucleoside triphosphate disphoshohydrolase, p2y2 antagonist and/or p2y6 antagonist |